For Better User Experience Please Use Potrait Mode.
OncoStem Diagnostics works on developing innovative tests to help plan and personalize cancer treatment. Our goal is to use the latest in technology to redefine cancer treatment. CanAssist-Breast, our flagship product, helps clinicians formulate personalized therapeutic programs for their patients. The result – precision medicine that could shorten recovery time and improve the patients’ quality of life.
CanAssist-Breast is ISO 13485 accredited & CE (IVD) marked
Postsurgical treatment depends on the risk of cancer recurrence. CanAssist-Breast helps in accurate risk prediction, which means you are assured that the side effects of treatment do not outweigh their benefits. You get the treatment that your health warrants, which translates into shorter treatment cycles, lower costs and quicker recovery.
The benefit that a low-risk patient receives from chemotherapy usually hovers between 10-15%. This makes accurate risk prediction an all-important prerequisite for effective treatment. CanAssist-Breast is a quick and cost-effective test that helps in your quest to offer the most effective treatment.
CanAssist-Breast stratifies Hormone Receptor positive breast cancer patients as low- or high-risk for cancer recurrence and aids in personalized treatment planning.
Hypothesis driven biomarker selection
Gateway to rational drug design
on Indian patients
For Dr Bakre Sparing Breast Cancer Patients from Chemotherapy has been a Life Calling
A glimpse of the vision of OncoStem by Indian express
Silicon India speaks about OncoStem
E27 talks about OncoStem's flag-ship product CanAssist-Breast.
Oncostem Diagnostics Raises $6 Million Led By Sequoia India
About Dr. Manjiri in Smart CEO
OncoStem Diagnostics raises $6 mn led by Sequoia India, plans expansion globally
6 million reasons why you should know this cancer scientist
OncoStem Diagnostics launches CanAssist-Breast: An innovative breast cancer recurrence prediction test
About OncoStem Diagnostics, Published in ET
Signup for email alert
Stay tuned for your latest updates.